The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: A Southwest Oncology Group Study

Investigational New Drugs

Volumn 20, Issue 1, 2002, Pages 117-121

  Weick, James K ^a   Crowley, John J ^b   Hussein, Mohamed A ^c   Moore, Dennis F ^d   Barlogie, Bart ^e  

^a Hematology Oncology Associates   (United States)

^b Statistical Center   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Gemcitabine; Multiple myeloma; Phase II

Indexed keywords

GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; EVALUATION; FATIGUE; FEMALE; GRANULOCYTOPENIA; HEMATOLOGIC DISEASE; HUMAN; MALAISE; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL;

EID: 0036210569     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014493007347     Document Type: Article

References (27)

1. Cancer statistics 1999
2. Multiple myeloma
3. Long term survival in multiple myeloma
4. The treatment of multiple myeloma
5. Management of refractory myeloma: A review
6. Evaluation of Topotecan in Resistant and Relapsed Multiple Myeloma: A Southwest Oncology Group Study
7. Gemcitabine metabolism, mechanics of action, and self-potentiation
8. Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is critical event
9. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine)
10. Activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units
11. Difluorodeoxycytidine (dFdC, gemcitabine): A phase I study
12. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. A randomized trial
13. Gemcitabine in non-small cell lung cancer
14. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in pre viously treated ovarian cancer patients
15. Advanced breast cancer: A Phase II trial with gemcitabine
16. A Phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck
17. Prognostic factors in a randomized trial of Gemcitabine (GEM) versus 5-FU as first-line therapy in advanced pancreatic cancer and in pancreatic cancer patients failing 5-FU who received gemcitabine as a palliative therapy
18. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: Experience in 44 patients
19. Gemcitabine in the treatment in refractory Hodgkin's disease: Results of a Phase II study
20. Gemcitabine safety overview
21. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials
22. Clinical application of research on angiogenesis
23. Novel approaches in myeloma therapy
24. Arsenic trioxide and ascorbic acid induced apoptosis in primary myeloma cells from chemo-resistant patients
25. New sources and new antitumor drugs in development